Publications by authors named "Jeorg Ermann"
Article Synopsis
- The study aimed to evaluate the long-term safety and effectiveness of ixekizumab (IXE) over three years, focusing on data from several clinical trials known as the COAST program.*
-
- In the COAST-Y trial, patients continued their IXE treatment and were monitored for treatment-emergent adverse events (TEAEs), with a notable incidence rate of 38.0 per 100 patient-years, primarily involving mild to moderate infections and injection site reactions.*
-
- Results indicated that patients receiving IXE maintained significant improvements in disease activity over three years, reinforcing IXE’s established long-term safety and efficacy in treating Ankylosing Spondylitis.*
